Switch to:
Also traded in: Argentina, Germany, Mexico, Switzerland, UK, USA

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 0.24
GLAXF's Cash to Debt is ranked lower than
83% of the 761 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.33 vs. GLAXF: 0.24 )
Ranked among companies with meaningful Cash to Debt only.
GLAXF' s Cash to Debt Range Over the Past 10 Years
Min: 0.06  Med: 0.46 Max: N/A
Current: 0.24
Equity to Asset 0.01
GLAXF's Equity to Asset is ranked lower than
97% of the 704 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.63 vs. GLAXF: 0.01 )
Ranked among companies with meaningful Equity to Asset only.
GLAXF' s Equity to Asset Range Over the Past 10 Years
Min: 0.01  Med: 0.24 Max: 0.4
Current: 0.01
0.01
0.4
Interest Coverage 1.92
GLAXF's Interest Coverage is ranked lower than
85% of the 475 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 21.69 vs. GLAXF: 1.92 )
Ranked among companies with meaningful Interest Coverage only.
GLAXF' s Interest Coverage Range Over the Past 10 Years
Min: 0.81  Med: 9.42 Max: 24.87
Current: 1.92
0.81
24.87
F-Score: 5
Z-Score: 1.17
M-Score: -2.63
WACC vs ROIC
9.19%
4.59%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) 5.33
GLAXF's Operating margin (%) is ranked lower than
52% of the 707 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.73 vs. GLAXF: 5.33 )
Ranked among companies with meaningful Operating margin (%) only.
GLAXF' s Operating margin (%) Range Over the Past 10 Years
Min: 1.68  Med: 28.24 Max: 34.91
Current: 5.33
1.68
34.91
Net-margin (%) 0.12
GLAXF's Net-margin (%) is ranked lower than
64% of the 710 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.01 vs. GLAXF: 0.12 )
Ranked among companies with meaningful Net-margin (%) only.
GLAXF' s Net-margin (%) Range Over the Past 10 Years
Min: 5.76  Med: 19.43 Max: 23.2
Current: 0.12
5.76
23.2
ROE (%) 0.75
GLAXF's ROE (%) is ranked higher than
64% of the 742 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.15 vs. GLAXF: 0.75 )
Ranked among companies with meaningful ROE (%) only.
GLAXF' s ROE (%) Range Over the Past 10 Years
Min: 17.3  Med: 61.93 Max: 84.89
Current: 0.75
17.3
84.89
ROA (%) 0.06
GLAXF's ROA (%) is ranked lower than
64% of the 766 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.68 vs. GLAXF: 0.06 )
Ranked among companies with meaningful ROA (%) only.
GLAXF' s ROA (%) Range Over the Past 10 Years
Min: 3.84  Med: 13.20 Max: 20.43
Current: 0.06
3.84
20.43
ROC (Joel Greenblatt) (%) 14.14
GLAXF's ROC (Joel Greenblatt) (%) is ranked higher than
58% of the 759 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 14.13 vs. GLAXF: 14.14 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
GLAXF' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 40.79  Med: 85.34 Max: 107.42
Current: 14.14
40.79
107.42
Revenue Growth (3Y)(%) -4.00
GLAXF's Revenue Growth (3Y)(%) is ranked lower than
76% of the 601 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.60 vs. GLAXF: -4.00 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
GLAXF' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -4  Med: 4.85 Max: 15.3
Current: -4
-4
15.3
EBITDA Growth (3Y)(%) -18.20
GLAXF's EBITDA Growth (3Y)(%) is ranked lower than
86% of the 553 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.40 vs. GLAXF: -18.20 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
GLAXF' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -18.2  Med: 6.60 Max: 17.4
Current: -18.2
-18.2
17.4
EPS Growth (3Y)(%) -18.10
GLAXF's EPS Growth (3Y)(%) is ranked lower than
79% of the 510 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.30 vs. GLAXF: -18.10 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
GLAXF' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -30.3  Med: 5.05 Max: 51.3
Current: -18.1
-30.3
51.3
» GLAXF's 10-Y Financials

Financials (Next Earnings Date: 2016-10-26)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Insider Trades

Latest Guru Trades with GLAXF

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare:NYSE:ABBV, NYSE:SNY, NYSE:LLY, OTCPK:BAYZF, NYSE:AZN, NYSE:BMY, NYSE:MRK, OTCPK:ALPMF, OTCPK:OTSKY, OTCPK:OPHLY, OTCPK:DSNKY, NYSE:NVS, OTCPK:KYKOF, OTCPK:SNPHF, OTCPK:CHJTF, OTCPK:PTKFF, OTCPK:MAYNF, OTCPK:GWPRF, NAS:HCM, AMEX:TXMD » details
Traded in other countries:GSK.Argentina, GS7.Germany, GSK N.Mexico, GSK.Switzerland, GSK.UK, GSK.USA,
GlaxoSmithKline PLC creates, discovers, develops, manufactures and markets pharmaceutical products including vaccines, over-the-counter (OTC) medicines and health-related consumer products.

GlaxoSmithKline PLC was incorporated on 6 December 1999 in the United Kingdom. The Company creates, discovers, develops, manufactures and markets pharmaceutical products including vaccines, over-the-counter (OTC) medicines and health-related consumer products. Its principal pharmaceutical products include medicines in the following therapeutic areas: respiratory, anti-viral, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterial, oncology and emesis, dermatology, rare diseases, immuno-inflammation, vaccines and HIV. The Company is a science-led healthcare company that researches and develops products in three areas - pharmaceutical, vaccines and consumer healthcare. Its Pharmaceuticals business develops and makes medicines to treat acute and chronic diseases. Its portfolio is made up of both patent-protected and off patent medicines. Its products include treatment for Infectious Diseases, Cancer, Epilepsy, Heart Disease, Asthma and Chronic obstructive pulmonary disease, and HIV/AIDS. Its Vaccine business has approximately 900 million doses distributed to 170 countries in 2012. It produces paediatrics and adult vaccines to prevent a range of infectious diseases including: Hepatitis A and B, Diphtheria, Tetanus and Whooping cough, Measles, Mumps and Rubella, Polio, Typhoid, Influenza, Bacterial Meningitis. The consumer healthcare business, markets consumer health products based on scientific innovation. It has products in four main categories: Oral care, Nutritional, Total wellness, and Skin health. Its brands include Sensodyne, Panadol and Horlicks. Its drinks brands are Lucozade and Ribena. The Oral Care brands, alli and Abreva.

Ratios

vs
industry
vs
history
Forward P/E 18.73
GLAXF's Forward P/E is ranked lower than
59% of the 81 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 16.39 vs. GLAXF: 18.73 )
Ranked among companies with meaningful Forward P/E only.
N/A
Price/Owner Earnings (ttm) 27.90
GLAXF's Price/Owner Earnings (ttm) is ranked lower than
52% of the 282 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 34.57 vs. GLAXF: 27.90 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
GLAXF' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 4.81  Med: 16.41 Max: 45.91
Current: 27.9
4.81
45.91
P/B 143.05
GLAXF's P/B is ranked lower than
99% of the 823 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.89 vs. GLAXF: 143.05 )
Ranked among companies with meaningful P/B only.
GLAXF' s P/B Range Over the Past 10 Years
Min: 5.48  Med: 9.29 Max: 143.05
Current: 143.05
5.48
143.05
P/S 3.27
GLAXF's P/S is ranked lower than
56% of the 767 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.74 vs. GLAXF: 3.27 )
Ranked among companies with meaningful P/S only.
GLAXF' s P/S Range Over the Past 10 Years
Min: 1.94  Med: 2.80 Max: 4.22
Current: 3.27
1.94
4.22
PFCF 54.81
GLAXF's PFCF is ranked lower than
93% of the 221 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 21.52 vs. GLAXF: 54.81 )
Ranked among companies with meaningful PFCF only.
GLAXF' s PFCF Range Over the Past 10 Years
Min: 8.24  Med: 16.88 Max: 135.68
Current: 54.81
8.24
135.68
POCF 22.12
GLAXF's POCF is ranked lower than
70% of the 292 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 16.35 vs. GLAXF: 22.12 )
Ranked among companies with meaningful POCF only.
GLAXF' s POCF Range Over the Past 10 Years
Min: 6.61  Med: 12.37 Max: 27.31
Current: 22.12
6.61
27.31
EV-to-EBIT 69.55
GLAXF's EV-to-EBIT is ranked lower than
85% of the 591 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 21.71 vs. GLAXF: 69.55 )
Ranked among companies with meaningful EV-to-EBIT only.
GLAXF' s EV-to-EBIT Range Over the Past 10 Years
Min: 6.3  Med: 10.60 Max: 72.3
Current: 69.55
6.3
72.3
EV-to-EBITDA 33.73
GLAXF's EV-to-EBITDA is ranked lower than
69% of the 625 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 16.97 vs. GLAXF: 33.73 )
Ranked among companies with meaningful EV-to-EBITDA only.
GLAXF' s EV-to-EBITDA Range Over the Past 10 Years
Min: 5.6  Med: 9.10 Max: 35.1
Current: 33.73
5.6
35.1
Shiller P/E 17.46
GLAXF's Shiller P/E is ranked higher than
88% of the 151 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 50.39 vs. GLAXF: 17.46 )
Ranked among companies with meaningful Shiller P/E only.
GLAXF' s Shiller P/E Range Over the Past 10 Years
Min: 11.71  Med: 14.95 Max: 20.67
Current: 17.46
11.71
20.67
Current Ratio 0.93
GLAXF's Current Ratio is ranked lower than
84% of the 682 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.39 vs. GLAXF: 0.93 )
Ranked among companies with meaningful Current Ratio only.
GLAXF' s Current Ratio Range Over the Past 10 Years
Min: 0.93  Med: 1.27 Max: 1.78
Current: 0.93
0.93
1.78
Quick Ratio 0.63
GLAXF's Quick Ratio is ranked lower than
86% of the 682 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.78 vs. GLAXF: 0.63 )
Ranked among companies with meaningful Quick Ratio only.
GLAXF' s Quick Ratio Range Over the Past 10 Years
Min: 0.63  Med: 0.99 Max: 1.42
Current: 0.63
0.63
1.42
Days Inventory 202.72
GLAXF's Days Inventory is ranked lower than
82% of the 666 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 114.20 vs. GLAXF: 202.72 )
Ranked among companies with meaningful Days Inventory only.
GLAXF' s Days Inventory Range Over the Past 10 Years
Min: 167.28  Med: 190.92 Max: 202.64
Current: 202.72
167.28
202.64
Days Sales Outstanding 86.98
GLAXF's Days Sales Outstanding is ranked lower than
60% of the 624 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 73.90 vs. GLAXF: 86.98 )
Ranked among companies with meaningful Days Sales Outstanding only.
GLAXF' s Days Sales Outstanding Range Over the Past 10 Years
Min: 54.62  Med: 74.32 Max: 93.9
Current: 86.98
54.62
93.9

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 5.13
GLAXF's Dividend Yield is ranked higher than
95% of the 603 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.48 vs. GLAXF: 5.13 )
Ranked among companies with meaningful Dividend Yield only.
GLAXF' s Dividend Yield Range Over the Past 10 Years
Min: 2.72  Med: 5.09 Max: 6.24
Current: 5.13
2.72
6.24
Dividend Growth (3y) 1.90
GLAXF's Dividend Growth (3y) is ranked lower than
64% of the 288 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.70 vs. GLAXF: 1.90 )
Ranked among companies with meaningful Dividend Growth (3y) only.
GLAXF' s Dividend Growth (3y) Range Over the Past 10 Years
Min: -12.6  Med: 7.00 Max: 20.8
Current: 1.9
-12.6
20.8
Forward Dividend Yield 4.48
GLAXF's Forward Dividend Yield is ranked higher than
95% of the 578 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.54 vs. GLAXF: 4.48 )
Ranked among companies with meaningful Forward Dividend Yield only.
N/A
Yield on cost (5-Year) 7.09
GLAXF's Yield on cost (5-Year) is ranked higher than
93% of the 707 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.93 vs. GLAXF: 7.09 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
GLAXF' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 3.76  Med: 7.04 Max: 8.63
Current: 7.09
3.76
8.63
3-Year Average Share Buyback Ratio -2.00
GLAXF's 3-Year Average Share Buyback Ratio is ranked higher than
63% of the 422 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -4.10 vs. GLAXF: -2.00 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
GLAXF' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -20.3  Med: 1.20 Max: 4.7
Current: -2
-20.3
4.7

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 2.60
GLAXF's Price/Projected FCF is ranked higher than
54% of the 344 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.59 vs. GLAXF: 2.60 )
Ranked among companies with meaningful Price/Projected FCF only.
GLAXF' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.97  Med: 1.61 Max: 21.79
Current: 2.6
0.97
21.79
Price/Median PS Value 1.17
GLAXF's Price/Median PS Value is ranked lower than
53% of the 734 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.14 vs. GLAXF: 1.17 )
Ranked among companies with meaningful Price/Median PS Value only.
GLAXF' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.71  Med: 1.17 Max: 3.34
Current: 1.17
0.71
3.34
Earnings Yield (Greenblatt) (%) 1.40
GLAXF's Earnings Yield (Greenblatt) (%) is ranked lower than
59% of the 844 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.90 vs. GLAXF: 1.40 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
GLAXF' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 1.4  Med: 9.50 Max: 15.8
Current: 1.4
1.4
15.8
Forward Rate of Return (Yacktman) (%) -0.03
GLAXF's Forward Rate of Return (Yacktman) (%) is ranked higher than
53% of the 325 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.60 vs. GLAXF: -0.03 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
GLAXF' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: 0.1  Med: 12.60 Max: 34.6
Current: -0.03
0.1
34.6

More Statistics

Revenue (TTM) (Mil) $36,959
EPS (TTM) $ 0.01
Beta1.11
Short Percentage of Float0.00%
52-Week Range $18.45 - 22.98
Shares Outstanding (Mil)4,872.40

Analyst Estimate

Dec16 Dec17 Dec18
Revenue (Mil $) 33,292 34,616 36,298
EPS ($) 1.22 1.27 1.28
EPS w/o NRI ($) 1.22 1.27 1.28
EPS Growth Rate
(3Y to 5Y Estimate)
2.51%
Dividends Per Share ($) 1.13 1.08 1.08
» More Articles for OTCPK:GLAXF

Headlines

Articles On GuruFocus.com
GlaxoSmithKline’s Sideways Dance May Pay Off in the Long Run Jul 22 2016 
Why Berkshire Hathaway Dumped Johnson & Johnson Jul 19 2016 
Andreas Halvorsen's Viking Global Gets Control of Stakes in 2 Companies for Backing Hot Biotech Jul 14 2016 
Investing in Big Pharma: Pointers on Pfizer Jul 14 2016 
Getting to Know VBI Vaccines Jul 13 2016 
Jeff Auxier Sells Precision Castparts, AT&T, Microsoft Jun 23 2016 
Steven Cohen Adds to Stake in Pernix Therapeutics Jun 07 2016 
PhaseRX: The Latest Pick From a Legendary VC Firm May 24 2016 
Kahn Brothers Adds to BP, GlaxoSmithKline Stakes May 10 2016 
A Closer Look Into Veritas Pharma Apr 21 2016 

More From Other Websites
GlaxoSmithKline Increases Top Line in 2Q16 Jul 30 2016
[$$] Cutting rates would be madhouse economics for the Bank of England Jul 29 2016
Glaxo (GSK) Beats Q2 Earnings Estimates, Revenues Up Y/Y Jul 28 2016
[$$] GlaxoSmithKline Helped and Hurt by Sterling’s Post-Brexit Fall Jul 27 2016
[$$] GlaxoSmithKline Helped and Hurt by Sterling's Post-Brexit Fall Jul 27 2016
GSK Plans £275m UK Investment After EU Vote Jul 27 2016
Why Fiat Chrysler, Coca-Cola, Anthem and 2 Other Stocks Are Moving Today Jul 27 2016
4 Surprising Quality Growth Stocks That Pay at Least a 5% Dividend Jul 27 2016
McDonald’s Joins Glaxo in Giving Jobs Boost to Post-Brexit U.K. Jul 27 2016
GSK invests $A481m in post-Brexit UK Jul 27 2016
GlaxoSmithKline invests $360 million in UK despite Brexit Jul 27 2016
GlaxoSmithKline invests 275 million pounds in UK despite Brexit Jul 27 2016
GlaxoSmithKline invests $360 mln in UK despite Brexit Jul 27 2016
Glaxo reports 2Q loss Jul 27 2016
GlaxoSmithKline CEO on Performance, Products, Growth Jul 27 2016
GlaxoSmithKline CEO: Strong Currency Tailwind Effect Jul 27 2016
Should you buy GlaxoSmithKline plc after today’s results? Jul 27 2016
Glaxo (GSK) Beats Q2 Earnings, Revenues Rise Y/Y Jul 27 2016
GlaxoSmithKline Rallies on Strong Quarterly Results Jul 27 2016
GSK results ride sterling's roller-coaster Jul 27 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)